Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
Austin I. Kim(Dana-Farber Cancer Institute), Mark A. Murakami(Harvard University), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Oreofe O. Odejide(Dana-Farber Cancer Institute), Salah Abdulkarim(Boston University), Megan Forsyth(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Erin M. Parry(Broad Institute), Amy Bessnow(Harvard University), Philippe Armand(Harvard University), Inhye E. Ahn(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), Christine E. Ryan(Dana-Farber Cancer Institute), Samantha Pazienza(Dana-Farber Cancer Institute), Michael Leukam(Beth Israel Deaconess Medical Center), Eric D. Jacobsen(Dana-Farber Cancer Institute), David Qualls(Memorial Sloan Kettering Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), Vanessa Kats(Boston University), Susan M Waisgerber(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Peter A. Riedell(University of Chicago)
Cited by 2
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k